Lunaphore Technologies SA, a Swiss medtech firm developing innovative next-generation devices for cancer tissue diagnostics*, announces closing of CHF 5.3M in Series B funding. Together with the CHF 6M convertible loan injected to the company in October 2017, the overall financing round amount has reached CHF 11.3M.

Read the full press release

This year, the United States and Canadian Academy of Pathology (USCAP) celebrated its 2018 Annual Meeting in Vancouver, Canada, which received over 4,500 national and international delegates.

Lunaphore attended the event with a booth, where the team was able to answer the questions from pathologists and other industry members. Lunaphore’s presence at the event raised great attention and turned out to be a great success as it was the first time the company attended an American pathology congress.

Our CTO, Diego Dupouy, was also present and presented a poster titled: “Ultra-rapid colocalized 4-plex staining thanks to microfluidic technology”.

We are looking forward to the USCAP Annual Meeting next year!